IMITREX PRETREATMENT DECISION SHOULD CHECK PATIENTS WITH CORONARY ARTERY RISKS, GLAXO SAYS; "DEAR DOCTOR" IS SECOND IN THREE MONTHS FOR MIGRAINE DRUG
Executive Summary
Glaxo is advising physicians to screen patients with risk factors for coronary artery disease before beginning treatment with its anti-migraine agent Imitrex (sumatriptan).